Insmed Incorporated (NASDAQ:INSM) Insider Sells $2,674,149.50 in Stock

Insmed Incorporated (NASDAQ:INSM) insider Martina M.D. Flammer sold 33,055 shares of the company’s stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $80.90, for a total value of $2,674,149.50. Following the completion of the sale, the insider now owns 138,053 shares of the company’s stock, valued at $11,168,487.70. This represents a 19.32 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Martina M.D. Flammer also recently made the following trade(s):

• On Tuesday, January 14th, Martina M.D. Flammer sold 1,384 shares of Insmed stock. The shares were sold at an average price of $68.72, for a total value of $95,108.48.
• On Friday, January 10th, Martina M.D. Flammer sold 6,172 shares of Insmed stock. The stock was sold at an average price of $63.64, for a total transaction of $392,786.08.
• On Tuesday, January 7th, Martina M.D. Flammer sold 3,344 shares of Insmed stock. The shares were sold at an average price of $65.91, for a total transaction of $220,403.04.

Insmed Price Performance

Shares of INSM opened at $79.95 on Monday. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The company’s fifty day moving average price is $72.88 and its 200-day moving average price is $73.09. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $82.04. The firm has a market capitalization of $14.30 billion, a PE ratio of -14.41 and a beta of 1.11.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on INSM shares. Guggenheim increased their price objective on shares of Insmed from $95.00 to $101.00 and gave the company a “buy” rating in a research note on Friday. HC Wainwright reaffirmed a “buy” rating and set a $90.00 target price on shares of Insmed in a research report on Friday, November 1st. JPMorgan Chase & Co. boosted their price target on Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Friday. Morgan Stanley raised their price objective on Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday. Finally, Truist Financial reiterated a “buy” rating and issued a $105.00 target price (up from $100.00) on shares of Insmed in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $85.00.

Institutional Trading of Insmed

Large investors have recently added to or reduced their stakes in the company. Vestal Point Capital LP raised its stake in shares of Insmed by 113.3% in the third quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock worth $116,800,000 after purchasing an additional 850,000 shares during the last quarter. TimesSquare Capital Management LLC purchased a new position in Insmed during the 3rd quarter worth approximately $35,322,000. Assenagon Asset Management S.A. lifted its stake in Insmed by 119.2% during the 3rd quarter. Assenagon Asset Management S.A. now owns 857,360 shares of the biopharmaceutical company’s stock valued at $62,587,000 after acquiring an additional 466,306 shares during the period. Victory Capital Management Inc. lifted its stake in Insmed by 209.9% during the 3rd quarter. Victory Capital Management Inc. now owns 455,959 shares of the biopharmaceutical company’s stock valued at $33,285,000 after acquiring an additional 308,819 shares during the period. Finally, Westfield Capital Management Co. LP purchased a new stake in shares of Insmed in the 3rd quarter valued at $18,377,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.